Alzheimer's Drug Examined for Use in Treatment-Resistant Depression
the Psychiatry Advisor take:
Researchers at the University of Texas Southwestern Medical Center are conducting research into using the dementia drug Namenda (memantine) as a therapy for treatment-resistant depression. Memantine, acts on the brain’s NMDA receptors, which are known to play a role in depression. The research could eventually lead to a treatment that blocks NMDA receptors and better controls depression with fewer side effects.
Memantine is chemically similar to ketamine, which is known to produce a fast-acting antidepressant effect in patients. However, ketamine’s other effects and recreational use make it unable to use for depression. But memantine reacts with the same brain receptors as ketamine, though researchers have found that it doesn’t produce the same antidepressant effect.
Identifying Fast-Acting Treatments for Resistant Depression
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Role of Expressed Emotion in Family Psychopathology
- Serum Uric Acid May Predict Bipolar Disorder in Patients With Depression
- Health and Social Factors Predict Changes in Depressive Symptoms in Women
- ASD Risk on Offspring With Prenatal Use of Medication Affecting Neurotransmitter System
- Group Cognitive Behavioral Therapy Is Effective Treatment for Adolescent Anxiety
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Cannabis Use, Cannabis Use Disorder Linked to Psychotic, Depressive Symptoms
- Association Between Opioid and Benzodiazepine Misuse and Suicidal Ideation
- The Intersection of Eating and Alcohol Disorders: Detecting and Managing "Drunkorexia"
- Heart Rate Variability Predicts Treatment Response in Anxious Depression
- Abstinence From Regular Cannabis Use Improves Memory Among Adolescents, Young Adults
- Effects of Mindfulness Meditation on Mood in Middle-Age, Older Adults
- How Does Accepting Blame Affect Future Medical Errors?
- Dementia Often Misclassified With Brief Cognitive Assessments
- Vitamin D Deficiency May Contribute to Elevated Interleukin-6 in Psychosis